In bioimaging, targeting allows refining the diagnosis by improving the sensitivity and especially the specificity for an earlier diagnosis. Two 111In-radiolabeled dendritic nanoprobes (DPs) (111In-2, 111In-3) and their model counterparts (111In-1, 111In-4) are designed and assessed for in vitro and in vivo tumor targeting efficiency in a murine melanoma models. Tumor uptake is correlated to dendrimer multivalency and reaches values as high as 12.7 ± 1.6% ID g-1 at 4 h post intravenous injection for 111In-3vs. 1.5 ± 0.5% ID g-1 for the unfunctionalized DP, and over 11% ID g-1 for any tumor weight whatsoever.